Guerbet cuts jobs as contrast agent market stagnates
This article was originally published in Clinica
Guerbet is to cut more than a tenth of its workforce in a restructuring programme aimed at improving the French company's position in the shrinking contrast agent market. The measures are expected to cost around Fr80 million ($13.5 million) and will be funded in 1998, which will result in a loss this year. The cuts are expected to result in annual savings of around Fr49 million.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.